- Report
- January 2025
Australia
From €1331EUR$1,500USD£1,150GBP
- Report
- January 2025
Argentina
From €1331EUR$1,500USD£1,150GBP
- Report
- January 2025
Albania
From €1331EUR$1,500USD£1,150GBP
- Report
- March 2024
Czech Republic
From €1331EUR$1,500USD£1,150GBP
- Report
- November 2021
Asia Pacific
From €12869EUR$14,500USD£11,118GBP
- Report
- November 2021
Global
From €30619EUR$34,500USD£26,454GBP
Prothrombin is a hematological drug used to treat and prevent blood clotting disorders. It is a form of vitamin K-dependent clotting factor, which is produced in the liver and is essential for normal blood clotting. Prothrombin is used to treat and prevent conditions such as deep vein thrombosis, pulmonary embolism, and stroke. It is also used to prevent bleeding in patients with liver disease or who are taking anticoagulants. Prothrombin is available in both injectable and oral forms.
The prothrombin market is highly competitive, with a number of companies offering products. Some of the major players in the market include Pfizer, Novo Nordisk, Sanofi, Bayer, and Merck. These companies offer a range of products, including injectable and oral forms of prothrombin, as well as generic versions. Show Less Read more